CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
优化 CAR-T 细胞治疗在血液系统恶性肿瘤中疗效的联合策略
英文原题：Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
查看英文原题
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已经彻底改变了血液系统恶性肿瘤的治疗格局。然而，耐药和复发仍然是突出的局限性，这与CAR-T 细胞持久性和疗效有限、肿瘤抗原下调或丢失、肿瘤对死亡信号的内在抵抗以及免疫抑制微环境有关。合理的联合治疗模式被认为是一种有前景的策略，可进一步释放CAR-T 细胞疗法的抗肿瘤潜力，可在CAR-T 细胞输注前作为预处理方案应用，也可在体外培养环境中应用，以及与CAR-T 细胞输注同时或之后应用。在这篇综述中，我们总结了联合策略，包括化疗、放疗、造血干细胞移植、靶向治疗和其他免疫治疗，以期进一步提高这一令人瞩目的疗法的有效性并造福更多患者。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies.
However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour antigens, intrinsic resistance of tumours to death signalling, and immune suppressive microenvironment. Rational combined modality treatments are regarded as a promising strategy to further unlock the antitumor potential of CAR T cell therapy, which can be applied before CAR T cell infusion as a conditioning regimen or in ex vivo culture settings as well as concomitant with or after CAR T cell infusion.
In this review, we summarize the combinatorial strategies, including chemotherapy, radiotherapy, haematopoietic stem cell transplantation, targeted therapies and other immunotherapies, in an effort to further enhance the effectiveness of this impressive therapy and benefit more patients.
论文信息
- 作者
- Xiao X、Wang Y、Zou Z、Yang Y、Wang X、Xin X、Tu S、Li Y
- 第一作者单位
- The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.China
- 通讯作者单位
- Department of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36091028 · DOI 10.3389/fimmu.2022.954235
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →